Clinical Trial

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Study acronym: PRRT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 20, 2026 (before its estimated June 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-09-12; most recent amendment 2026-03-18.
Status change: Enrolling by Invitation → Recruiting 2024-03-26
Trial Details
NCT Number NCT04090034
Lead Sponsor Methodist Health System
Conditions Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor
Enrollment 50 participants
Start Date 2024-03-28
Primary Completion 2026-06-28 (estimated)
Study Completion 2026-06-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-20